170 related articles for article (PubMed ID: 9373241)
21. Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo.
Wirger A; Perabo FG; Burgemeister S; Haase L; Schmidt DH; Doehn C; Mueller SC; Jocham D
Anticancer Res; 2005; 25(6B):4341-7. PubMed ID: 16309238
[TBL] [Abstract][Full Text] [Related]
22. Growth inhibition and induction of apoptosis by flavopiridol in rat lung adenocarcinoma, osteosarcoma and malignant fibrous histiocytoma cell lines.
Honoki K; Yoshitani K; Tsujiuchi T; Mori T; Tsutsumi M; Morishita T; Takakura Y; Mii Y
Oncol Rep; 2004 May; 11(5):1025-30. PubMed ID: 15069542
[TBL] [Abstract][Full Text] [Related]
23. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
[TBL] [Abstract][Full Text] [Related]
24. Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.
Bates DJ; Salerni BL; Lowrey CH; Eastman A
Cancer Biol Ther; 2011 Aug; 12(4):314-25. PubMed ID: 21768777
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway.
Nguyen DM; Schrump WD; Tsai WS; Chen A; Stewart JH; Steiner F; Schrump DS
J Thorac Cardiovasc Surg; 2003 May; 125(5):1132-42. PubMed ID: 12771887
[TBL] [Abstract][Full Text] [Related]
26. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis.
Wittmann S; Bali P; Donapaty S; Nimmanapalli R; Guo F; Yamaguchi H; Huang M; Jove R; Wang HG; Bhalla K
Cancer Res; 2003 Jan; 63(1):93-9. PubMed ID: 12517783
[TBL] [Abstract][Full Text] [Related]
27. The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Miyashita K; Shiraki K; Fuke H; Inoue T; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Aug; 18(2):249-56. PubMed ID: 16820931
[TBL] [Abstract][Full Text] [Related]
28. The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.
Rosato RR; Almenara JA; Cartee L; Betts V; Chellappan SP; Grant S
Mol Cancer Ther; 2002 Feb; 1(4):253-66. PubMed ID: 12467221
[TBL] [Abstract][Full Text] [Related]
29. Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase.
Matranga CB; Shapiro GI
Cancer Res; 2002 Mar; 62(6):1707-17. PubMed ID: 11912144
[TBL] [Abstract][Full Text] [Related]
30. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.
Motwani M; Li X; Schwartz GK
Clin Cancer Res; 2000 Mar; 6(3):924-32. PubMed ID: 10741717
[TBL] [Abstract][Full Text] [Related]
31. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
32. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.
Shapiro GI
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4270s-4275s. PubMed ID: 15217973
[TBL] [Abstract][Full Text] [Related]
33. Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol.
Li Y; Chinni SR; Senderowicz AM; Sarkar FH
Int J Oncol; 2000 Oct; 17(4):755-9. PubMed ID: 10995888
[TBL] [Abstract][Full Text] [Related]
34. Flavopiridol as a radio-sensitizer for esophageal cancer cell lines.
Sato S; Kajiyama Y; Sugano M; Iwanuma Y; Tsurumaru M
Dis Esophagus; 2004; 17(4):338-44. PubMed ID: 15569374
[TBL] [Abstract][Full Text] [Related]
35. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
Gao N; Dai Y; Rahmani M; Dent P; Grant S
Mol Pharmacol; 2004 Oct; 66(4):956-63. PubMed ID: 15235103
[TBL] [Abstract][Full Text] [Related]
36. Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol.
Semenov I; Akyuz C; Roginskaya V; Chauhan D; Corey SJ
Leuk Res; 2002 Mar; 26(3):271-80. PubMed ID: 11792416
[TBL] [Abstract][Full Text] [Related]
37. Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.
Dasmahapatra G; Almenara JA; Grant S
Mol Pharmacol; 2006 Jan; 69(1):288-98. PubMed ID: 16219908
[TBL] [Abstract][Full Text] [Related]
38. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
Cartee L; Wang Z; Decker RH; Chellappan SP; Fusaro G; Hirsch KG; Sankala HM; Dent P; Grant S
Cancer Res; 2001 Mar; 61(6):2583-91. PubMed ID: 11289135
[TBL] [Abstract][Full Text] [Related]
39. Rhabdoid tumor growth is inhibited by flavopiridol.
Smith ME; Cimica V; Chinni S; Challagulla K; Mani S; Kalpana GV
Clin Cancer Res; 2008 Jan; 14(2):523-32. PubMed ID: 18223228
[TBL] [Abstract][Full Text] [Related]
40. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells.
Jung C; Motwani M; Kortmansky J; Sirotnak FM; She Y; Gonen M; Haimovitz-Friedman A; Schwartz GK
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6052-61. PubMed ID: 14676132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]